Skip to main content
. 2017 Mar 22;12(3):e0174280. doi: 10.1371/journal.pone.0174280

Fig 4. Disease-free survival (DFS) of the comparison, UFUR <5 months, and UFUR ≥5 months groups.

Fig 4

The 5-year DFS rates of the comparison, UFUR <5 months, and UFUR ≥5 months groups were 62.3%, 64.3%, and 70.7%, respectively. UFUR: tegafur-uracil.